Elijah Ejun Huang

Dr. Elijah Ejun Huang

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2022 in Bioengineering
Verified
Journal Article
Open access
PDF file
EHElijah Ejun Huang
Elijah Ejun Huang
Ning ZhangNing Zhang
Ning Zhang
HSHuaishuang Shen
Huaishuang Shen
XLXueping Li
Xueping Li
MMMasahiro Maruyama
Masahiro Maruyama
Stuart B GoodmanStuart B Goodman
Stuart B Goodman
A critical-size bone defect is a challenging clinical problem in which a gap between bone ends will not heal and will become a nonunion. The current treatment is to harvest and transplant an autologous bone graft to facilitate bone bridging. To develop less invasive but equally effective treatment options, one needs to first have a comprehensive understanding of the bone healing process. Therefore, it is imperative to leverage the most advanced technologies to elucidate the fundamental concepts of the bone healing process and develop innovative therapeutic strategies to bridge the nonunion gap. In this review, we first discuss the current animal models to study critical-size bone defects. Then, we focus on four novel analytic techniques and discuss their strengths and limitations. These four technologies are mass cytometry (CyTOF) for enhanced cellular analysis, imaging mass cytometry (IMC) for enhanced tissue special imaging, single-cell RNA sequencing (scRNA-seq) for detailed transcriptome analysis, and Luminex assays for comprehensive protein secretome analysis. With this new understanding of the healing of critical-size bone defects, novel methods of diagnosis and treatment will emerge.

4 August 2022 in Journal of Orthopaedic Translation
Verified
Journal Article
Open access
EHElijah Ejun Huang
Elijah Ejun Huang
NZNing Zhang
Ning Zhang
EGEdward A. Ganio
Edward A. Ganio
HSHuaishuang Shen
Huaishuang Shen
XLXueping Li
Xueping Li
Stuart B GoodmanStuart B Goodman
Stuart B Goodman
A critical size bone defect is a clinical scenario in which bone is lost or excised due to trauma, infection, tumor, or other causes, and cannot completely heal spontaneously. The most common treatment for this condition is autologous bone grafting to the defect site. However, autologous bone graft is often insufficient in quantity or quality for transplantation to these large defects. Recently, tissue engineering methods using mesenchymal stem cells (MSCs) have been proposed as an alternative treatment. However, the underlying biological principles and optimal techniques for tissue regeneration of bone using stem cell therapy have not been completely elucidated. In this study, we compare the early cellular dynamics of healing between bone graft transplantation and MSC therapy in a murine chronic femoral critical-size bone defect. We employ high-dimensional mass cytometry to provide a comprehensive view of the differences in cell composition, stem cell functionality, and immunomodulatory activity between these two treatment methods one week after transplantation. We reveal distinct cell compositions among tissues from bone defect sites compared with original bone graft, show active recruitment of MSCs to the bone defect sites, and demonstrate the phenotypic diversity of macrophages and T cells in each group that may affect the clinical outcome. Our results provide critical data and future directions on the use of MSCs for treating critical size defects to regenerate bone. Translational Potential of this article: This study showed systematic comparisons of the cellular and immunomodulatory profiles among different interventions to improve the healing of the critical-size bone defect. The results provided potential strategies for designing robust therapeutic interventions for the unmet clinical need of treating critical-size bone defects.

10 September 2025 in Journal of Orthopaedic Translation
Verified
Journal Article
Open access
Ning ZhangNing Zhang
Ning Zhang
JYJie Yuan
Jie Yuan
XLXueping Li
Xueping Li
NSNi Su
Ni Su
YWYiyun Wang
Yiyun Wang
Stuart B GoodmanStuart B Goodman
Stuart B Goodman
Bone defects resulting from various causes present significant challenges in obtaining robust bone healing. This clinical scenario is particularly difficult in cases involving large bone defects, often leading to delayed union or non-union. Autogenous bone graft is the gold standard, but it is limited by the quantity and quality of available bone. Mesenchymal stem cells (MSCs) have shown promise in enhancing bone defect healing; however, the mechanisms by which MSCs modify the local bone microenvironment and interact with other cells early in the healing process are not fully understood. Elucidating and modulating the early biological events relevant to the healing of bone defects could lead to novel therapies to obtain a more expeditious and complete outcome. Critical-size femoral defects were created in 10 to 12-week-old BALB/c male mice and fixed with an external fixation device. Four weeks after the generation of the defect, secondary surgeries were performed. Mice were randomized into three groups based on the secondary surgery: Empty group - surgery was performed without implanting scaffolds or cells. Sc group - a 2 mm diameter cylindrical microribbon (μRB) scaffold was implanted into the defect site. Sc + MSC group - a scaffold embedded with MSCs was implanted into the bone defect site. One week after the secondary surgeries, the entire tissue within the bone defect site was harvested for single-cell RNA sequencing (scRNA-seq). Uniform manifold approximation and projection (UMAP) plots with quality filtered cells from three groups were used to identify the cell distributions in the defects. We identified thirteen populations and annotated each cluster using UMAP with Louvain clustering on combined single cells of three groups based on marker gene expression. Different cell compositions were revealed, especially the proportion of various types of immune cells in the Sc vs Sc + MSC groups. MSCs and osteoblastic lineage cells (MSC/Osteo), and osteoclasts were almost exclusively found in the Sc + MSC group. Differential gene expression and pathway analysis in major cell populations identified immune cell changes and inflammatory changes in the presence of implanted MSCs. Cell-cell communications revealed a greater number of interactions between different cell types in the Sc and Sc + MSC groups. More interactions among MSCs, macrophages, and T cells were observed in Sc + MSC groups. MSC demonstrated the highest outgoing interaction strength in all groups. In the critical-size bone defect model, a combination of MSCs with μRB scaffolds showed an increased presence of mesenchymal lineage cells and promoted the further recruitment of macrophages and osteoclasts at 1 week. This alteration in the local immune landscape and microenvironment could enhance the cellular dynamics of critical cell populations that are important to osteogenesis. Optimizing this cellular crosstalk early in the healing process could potentially augment MSC-based therapies for subsequent bone regeneration of critical-size bone defects. The results of our study provide a detailed transcriptional roadmap for local immune modulation by MSCs in scaffolds, supporting the optimization of robust strategies for MSC-based treatments of long bone critical-size defects in future clinical applications.